Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
China Resources Pharmaceutical Group Ltd. ( (HK:3320) ) has provided an announcement.
CR Double-Crane released its unaudited financial results for the first quarter of 2025, reporting a slight decrease in revenue compared to the previous year, but an increase in net profit. The company’s total assets and owner’s equity have grown, while cash and cash equivalents have decreased. Stakeholders are advised to exercise caution as the financials are unaudited and may be subject to adjustments.
More about China Resources Pharmaceutical Group Ltd.
China Resources Double-Crane Pharmaceutical Co., Ltd. is a pharmaceutical company incorporated in China, with shares listed on the Shanghai Stock Exchange. It is a subsidiary of China Resources Pharmaceutical Group Limited, which holds a 60.24% indirect ownership.
YTD Price Performance: -19.26%
Average Trading Volume: 1,550
Technical Sentiment Signal: Buy
Current Market Cap: €3.5B
See more insights into 3320 stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue